Resverlogix
Late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses.
Launch date
Employees
Market cap
AUD18.8m
Enterprise valuation
AUD33m (Public information from Sep 2024)
Share price
CAD0.07 RVX.TO
Calgary Alberta (HQ)
Financials
Estimates*
USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
EBITDA | (32.6m) | (38.9m) | (37.1m) | (74.2m) | (14.9m) | (11.7m) | (5.2m) |
Profit | (44.6m) | (54.6m) | (157m) | 118m | (24.8m) | (3.6m) | (16.7m) |
EV / EBITDA | -11.5x | -13.4x | -9.3x | -2.9x | -10.5x | -6.6x | -16.3x |
R&D budget | 28.9m | 35.4m | 31.1m | 15.8m | 4.5m | 5.5m | 3.2m |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
$25.0m | Post IPO Equity | ||
N/A | $1.8m | Post IPO Equity | |
N/A | $1.6m | Post IPO Equity | |
N/A | $2.3m | Post IPO Equity | |
N/A | $10.0m | Post IPO Equity | |
N/A | N/A | Early VC | |
N/A | CAD21.8m | Post IPO Equity | |
N/A | $2.0m | Post IPO Equity | |
* |
| $6.0m | Post IPO Convertible |
Total Funding | AUD80.2m |
Related Content
Recent News about Resverlogix
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.